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Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor commonly inactivated
in glioblastoma multiforme (GBM), but the prognostic significance of PTEN remains controversial. Here, we
demon- strate significant prognostic value of combined PTEN mutation and expression for the survival of patients
with GBM on the basis of analysis of large-scale cancer genomic data. PTEN nonsense mutations associated with
sig- nificantly shorter disease-free survival and overexpression of PTEN protein linked to shorter disease-free and
overall survival of patients with GBM. PTEN nonsense mutations correlated with decreased p53 and Gata3 protein
levels and increased genomic instability in human GBM tissues. Expression of nonsense PTEN mutant decreased
p53 and Gata3 levels, producing increased DNA damage both in vitro and in vivo. Mice carrying xenograft tumors
with nonsense PTEN mutant displayed significantly shorter survival. Our data demonstrated the prognostic value
of combined PTEN mutation and protein expression for patients with GBM and highlighted distinct biologic effects
of nonsense and missense mutations of PTEN.
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Glioblastoma multiforme (GBM) is the most common malignant
brain tumor and one of the most aggressive human cancers, with a
mean survival time of less than 1 year after diagnosis [1]. Loss of
10q, including phosphatase and tensin homolog deleted on
chromosome 10 (PTEN ) gene, is the most common alteration
associated with GBM (70% incidence) [2]. PTEN is a tumor
suppressor that acts as a phosphatase for the lipid signaling
intermediate phosphatidylinositol-3,4,5-trisphosphate (PIP3), pro-
ducing phosphatidylinositol-4,5- bisphosphate. PIP3 anchors AKT
to the membrane, where AKT is activated through its phosphor-
ylation by phosphoinositide-dependent kinase-1 (PDK1) and
mammalian target of rapamycin complex 2 (mTORC2). AKT
phosphorylates numerous targets to transduce sig- nals for growth,
proliferation, and survival [3]. In addition to its effect on PIP3/AKT
pathway, PTEN also regulates p53 function. Mouse double minute
2 homolog (MDM2) is a substrate of AKT, thus acti- vation of
AKT on PTEN loss results in MDM2 phosphorylation and
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also physically associates with p53 to enhance its DNA binding
ability [5]. The domains within PTEN include a phosphatidylino-
sitol-4, 5-bisphosphate–binding region, a phosphatase domain, a C2
domain, with a C-terminal tail containing two rich in proline,
glutamic acid, serine, and threonine (PEST) domains for degrada-
tion and a post synaptic density (PDZ) interaction motif
(Figure 1A). Mutations of PTEN in GBM include missense,
nonsense, frameshift, and splice site mutations distributed through-
out the gene, causing disruption of the phosphatase domain by
truncation or instability. The most frequently observed mutations in
central nervous system (CNS) tumors are amino acid substitutions
at arginine 173 and nonsense mutation at arginine 130. TheA
C
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Figure 1. Distinct effects of PTEN mutations on DFS of patients with g
GBM database. Missense, nonsense, and frameshift mutations are re
on position Arg130 and missense mutations on Arg173 represent the m
phosphatase tensin–type domain. (B) Effects of PTENmutation, expre
effects of different factors on DFS time were analyzed using Cox reg
with 95% CIs (upper and lower bars). Nonsense PTEN mutation and
with shorter DFS (P b .05, star signs). (C) Kaplan-Meier survival tests
nonsense mutations than those carrying missense mutations (left pan
also display significantly shorter DFS when compared to all other ca
panel. (D) GBM cases overexpressing Pten protein display shorter DF
.05, star signs).preferential selection of these “hot spots” suggests that mutants of
PTEN may not confer equal oncogenic effects in GBM [6].
The prognostic significance of PTEN in GBM is still a matter of
debate. Although multiple clinical studies have suggested that PTEN
mutation in glioma has no correlation with survival or chemosensi-
tivity [7–10], some other studies have associated loss of function of
PTEN with a more adverse outcome [11–13]. Unfortunately, many
of these studies lack the sample size or thorough evaluation of PTEN
genetic alterations to make concrete conclusions. To precisely
evaluate the genuine prognostic significance of PTEN function in
brain malig- nancies, comprehensive analysis of GBM at the genetic
and expression levels on a large number of morphologically well-
defined patients is required [14].B
lioblastoma. (A) The mutation spectrum of PTEN gene in the TCGA
spectively plotted in red, blue, and green. The nonsense mutations
ost frequent mutations in GBM, which are in close relation with the
ssion, and promoter methylation on DFS of patients with GBM. The
ression, and the HR for each indicated factor is plotted (round dot)
increased Pten protein level are independent factors that correlate
suggest significantly shorter DFS for patients with GBM carrying
el) or wild-type PTEN (middle panel). Nonsense mutations of PTEN
ses (right panel). The corresponding P values are indicated in each
S than other cases, as indicated by Kaplan-Meier survival test (P b
198 PTEN Mutation and Expression in Glioblastoma Survival Xu et al. Translational Oncology Vol. 7, No. 2, 2014In the present study, we perform a comprehensive analysis on the
prognostic value of PTEN status in patients with GBM on the basis of
large-scale cancer genomic data. The 586 GBM cases included in this
study were well defined in both clinicopathologic and genomic/
proteomic aspects and thus may add an important answer to this
controversial field. We also analyze the effects of PTEN mutations on
different signaling proteins and experimentally validated the results.
By these efforts, we aim to provide mechanistic explanations for the
distinct effects of PTEN mutations.
Materials and Methods
Plasmid Construction
The vectors expressing wild-type PTEN were cloned by inserting
cDNAs into pcDNA3 vectors through the NheI and XhoI restriction
sites. All mutant vectors were generated by site-directed mutagenesis
polymerase chain reactions (Roche, Basel, Switzerland).
Cell Culture and Western Blot Analysis
The Ishikawa cells were purchased from the American Type
Culture Collection (Manassas, VA) and were passaged in our
laboratory for less than 6 months. Cells were grown in Dulbecco’s
Modified Eagle’s Medium supplemented with glutamine, pyruvate,
antibiotics, and 10% fetal calf serum in a humidified atmosphere
containing 5% CO2 at 37°C.
Cell lysate proteins were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (10% gels) and transferred to
nitro- cellulose membranes. Protein amounts were quantified using
the Bradford method, and equal protein amounts were loaded to the
gel. Membranes were blocked in TBS with 0.05% Tween 20 (TBST)
containing 5% nonfat dry milk powder for 1 hour. Western blots
were probed with primary antibodies for 1 hour, washed three times
with TBST, and then incubated with the appropriate secondary anti-
bodies for 30 minutes. Membranes were then washed with TBST
three times before developing with SuperSignal West Dura chemi-
luminescent substrate (Pierce, Rockford, IL).
The Comet Assay for Measuring DNA Damage
The comet assay used to measure DNA damage has been described
previously [15]. Briefly, cells were treated with 20 μM etoposide
(Sigma, St Louis, MO) for 4 hours, and the damage distribution was
measured as tail moment (product of tail length and fraction of
DNA). Cells were harvested and resuspended in Hank’s Balanced Salt
Solution (Sigma) with 10% DMSO and 0.5 M EDTA. The cell
suspension was then suspended in 0.7% low-melting agarose at 37°C
(Sigma) and layered on to comet slides (Trevigen, Gaithersburg,
MD). The cells were then lysed in lysis solution containing 2.5 M
NaCl, 100 mM pH 8.0 EDTA, 10 mM Tris-HCl, 1% Triton X
(Sigma) at 4°C for 1 hour.
Denaturation was carried out for 40 minutes, in chilled alkaline
elec- trophoresis buffer (pH 13.0-13.7). Electrophoresis was
subsequently carried out for 20 minutes. Slides were immersed in
neutralization buffer (500 mM Tris-HCl, pH 7.4), dehydrated, dried
and stained with SYBR Green dye (Invitrogen, Carlsbad, CA), and
scored with OpenComet plugin of ImageJ software. The images were
captured using fluorescence microscope (Carl Zeiss, Oberkochen,
Germany) equipped with triple-band filter. Fifty comets per sample
were randomly selected and analyzed. The extent of DNA damage
was expressed as tail moment, which corresponded to the fraction of
the DNA in the tail of the comet.In Vivo Experiments
Briefly, male BALB/c athymic nude mice (4-5 weeks old) were
obtained from the Experimental Animal Center of Shanghai Insti-
tutes for Biological Sciences (Shanghai, China). Mice were randomly
divided into the following two groups: nonsense group and missense
group (15 mice per group). Nonsense-group mice were injected sub-
cutaneously into the right flank with 1.0 × 107 Ishikawa cells stably
transfected with PTEN nonsense mutant (R130*), whereas the
missense-group mice were injected with 1.0 × 107 Ishikawa cells bear-
ing PTEN missense mutant (R173H) to establish xenograft models.
Tumor diameters were measured with digital calipers, and tumor vol-
ume was calculated by the following formula: tumor volume (mm3) =
shorter diameter2 × longer diameter/2. The tumor volume data are
pre- sented as means ± SD (n = 15). Our study was approved by the
Animal Care and Use Committee of the Renji Hospital affiliated to
Shanghai Jiao Tong University School of Medicine. All animal
procedures were performed according to the guidelines developed
by the China Council on Animal Care and the protocol approved by
the Renji Hospital affiliated to Shanghai Jiao Tong University School
of Medicine.
Cancer Genomic and Clinical Data
The genomic sequencing and survival data analyzed in this study
were obtained from The Cancer Genome Atlas (TCGA) GBM data
set [16]. The published versions of these data sets include 586 cancer
cases with sequencing data and clinical information.
Reverse Phase Protein Array Data
The corresponding reverse phase protein array (RPPA) data of
TCGA GBM data set were obtained using the cBioPortal online data
portal (Memorial Sloan-Kettering Cancer Center, New York, NY)
[17], which include quantified expression of 122 proteins and 43
phosphoproteins involved in various signaling pathways. Exam- ples
of such pathways include p53 signaling, retinoblastoma (RB), AMP-
activated protein kinase (AMPK), PTEN, phosphatidylinositol 3-
kinase (PI3K)/protein kinase B (PKB), receptor tyrosine kinase
(RTK)/RAS GTPase, and epidermal growth factor receptor signaling,
and other sequences. A complete list of antibodies in the protein
micro- array can be accessed from TCGA data portal (http://tcga-
data.nci.nih. gov/tcga/, Memorial Sloan-Kettering Cancer Center).
The patients with upper or lower quarter Pten protein expression
were determined according to the levels detected by RPPA
(respectively ranked as 25% highest or 25% lowest).
Drug Sensitivity Profile Data
We obtained the sensitivity profiles of 59 human brain tumor cell
lines to 131 anticancer drugs from the Cancer Cell Line Encyclo-
pedia (CCLE; Broad Institute, Cambridge, MA) database [18]. The
half-maximal inhibitory concentration (IC50) was used as a measure
of the effectiveness of a drug on the cell lines. The mutation spectrum
of TP53 in these cell lines was similar with that in the TCGA
data sets.
Survival Analysis
Survival analysis was carried out in R program using the “survival”
package as described previously [19]. In the Kaplan-Meier (log-rank)
survival test and Cox regression models, the censored status is in-
dicated when the patient was still alive (or cancer free) at the time of
follow-up. The Cox regression model included cancer type as a
covariant, and the P value for mutation type is calculated after
C D
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Figure 2. PTEN nonsense mutations increase genomic instability.
(A) Fraction of genome with CNA of patients with GBM carrying
different PTEN mutations. Each blue dot represents the CNA
fraction (percentage value) of one case, and the average values
were compared between patients carrying wild-type PTEN or
missense, nonsense, or frameshift mutations using Mann-Whitney
test. Missense and nonsense mutations showed significantly
increased CNA fraction compared to the wild type (P b .05). (B)
Nonsense PTEN mutations asso- ciate with increased number of
mutations in the genomes of patients with GBM. The number of
mutations in the genomes of patients with GBM was compared
between wild-type, missense, nonsense, and frameshift groups
using Mann-Whitney test. (C and D) Nonsense PTEN mutations
associate with significantly lower levels of p53 and Gata3 proteins.
The protein levels of p53 or Gata3 (as quantified by RPPAs) were
compared between GBM cases with different PTEN genotypes
(wild-type, missense, nonsense, or frameshift mutations) using
Mann-Whitney test.
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95% confidence intervals (CIs) were also determined for each
mutation. The effects of different p53 mutations were compared to
nonsense mutations as an indication of gain-of-function (GOF) effect.
Clustering Analysis
The GBM cases with either increased or decreased PTEN protein
level were clustered according to their patterns of signaling protein
expression (on the basis of RPPA data). The hierarchical clustering
was carried out using the Cluster program (Pearson correlation,
average linkage) and visualized by TreeView (University of California
at Berkeley, CA) [20]. The functional profiling of each protein cluster
was performed using the g:Profiler annotation tool (University of
Tartu, Estonia) under the criteria of P b .05.
Results
PTEN Nonsense Mutations Shorten Disease-Free Survival of
GBM Patients
We started by analyzing the effects of different PTENmutations on
disease-free survival (DFS) of patients with GBM, which reflects the
effectiveness of treatment and the tendency for cancer recurrence. A
total number of 586 patients with complete genomic sequencing and
clinical data from the TCGA GBM data set [16] were selected for
analysis in this study. The spectrum of PTEN mutation in the TCGA
GBM data set was similar to that reported previously [14], including
missense (51.2%), nonsense (16.9%), frameshift (24.9), and other
types of mutations (7%; Figure 1A). Using Cox propor- tional hazards
analysis, we analyzed the independent effects of PTEN mutation,
promoter methylation and expression (protein and mRNA levels by
arrays), genomic instability, and Karnofsky performance scale on DFS
of patients with GBM. Intriguingly, nonsense muta- tions of PTEN
associated with significantly shorter DFS (median, 3.8 months) than
other mutations or wild-type genotype (median, 7.2 months),
displaying higher HR of 3.26 (95% CI = 1.48-7.20; Figure 1, B
and C ). On the contrary, missense or frameshift muta- tions showed
no significant association with DFS of patients with GBM.Moreover,
overexpression of PTEN protein also associated with shorter DFS
(median, 6.0 months) than other cases (median, 7.0 months), with
increased HR of 1.31 (95% CI = 1.07-1.61; Figure 1, B and D). No
correlation was found between patient DFS and PTEN mRNA level
or promoter methylation, the number of mutations (as revealed by
genomic sequencing), or fraction of genome with copy number
alteration (CNA, an indication of genomic instability) in GBM cases.
PTEN Nonsense Mutations Increase Genomic Instability
The different effects of PTENmutations on DFS suggest that these
mutations also confer distinct biologic consequences. Because loss of
PTEN function has been linked to genomic instability and impaired
DNA repair ability [21], we compared the number of mutations and
fraction of genome with CNA in patients with GBM carrying
different types of PTEN mutations. Although missense, non- sense,
and frameshift mutations were all found to increase the fraction of
genome with CNA (Mann-Whitney test, P b .05; Figure 2A), only
nonsense mutation of PTEN associated with a higher number of
mutations in GBM tissues (Mann-Whitney test, P b .05; Figure 2B).
Furthermore, nonsense mutation of PTEN also linked to decreased
levels of p53 and Gata3 proteins (Mann-Whitney test, P b .05), but
such link was not evident for missense or frameshift mutations
(Figure 2, D and E).Validation of PTEN Mutational Effects In Vitro and In Vivo To
test the different effects of PTEN mutations, we stably trans- fected
“hotspot” PTEN nonsense (R130*) and missense (R173H) mutants
to the human Ishikawa cell strain. The Ishikawa strain has a PTEN-
null background [22], which facilitates the analysis on the effects of
exogenous mutants. We performed the comet assay to test whether
PTEN mutations could affect cell ability to repair DNA damage. As a
result, the nonsense mutation conferred significantly higher extent of
DNA damage when compared to the missense mutation (Figure 3, A
and B), thereby confirmed the findings in patients with GBM.
Furthermore, we validated the effects of PTENmutations on p53 and
Gata3 protein levels in Ishikawa cells using Western blot analysis. As
expected, the nonsense mutation of PTEN completely lost the wild-
type ability to increase p53 and Gata3 levels, but the missense
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Figure 3. Validation of PTEN mutational effects in vitro and in vivo. (A) Induction of DNA damage in etoposide -treated cells expressing
different PTEN mutants. The Ishikawa cells (PTEN null) were transfected with PTEN nonsense (R130*) or missense (R173H) mutants,
followed by treatment with 20 μM etoposide for 4 hours. The damage distribution was measured as tail moment. The bar plots indicate
the statistics of tail moments (means ± SE; *P b .05, t test). (B) Representative images of SYBR Green–stained comets. (C) Effects of
PTEN mutants on p53 and Gata3 levels as determined by Western blot analysis. The Ishikawa cells expressing nonsense (R130*) or
missense (R173H) mutations were lysed and subjected to Western blot analysisfor the detection of p53 and Gata3 protein levels. The
wild-type PTEN significantly increased p53 and Gata3 levels, but this ability was not found for the nonsensemutant. Themissensemutant
only mildly increased p53 and Gata3 levels. Full, uncut gels are shown in Figure W1. (D) Schematic representation of in vivo experimental
procedures. Ishikawa cells stably expressing nonsense (R130*) or missense (R173H) mutant PTEN were subcutaneously injected into
nude mice (n = 15 for each group). After formation of xenograft tumors, tissues were subjected to analyses as indicated. (E) Expression
levels of p53, Gata3, and γ-H2AX in xenograft tumor tissues as determined by immunohistochemistry (IHC) assay. The left panels show
representative IHC images from tumors carrying missense mutant, whereas the right panels include IHC images for nonsense mutant.
Nonsense PTEN mutation associated with decreased level of p53 and Gata3 and increased level of γ-H2AX (a marker for increased DNA
damage). (F) Representative images for mice carrying xenograft tumors that expressed nonsense mutant (larger, mouse on the right) or
missense PTEN mutant (on the left). (G) Statistics of tumor sizes for two experimental groups (means ± SE; *P b .05, t test). (H) Kaplan-
Meier survival analysis shows shorter survival of mice carrying nonsense PTEN mutation (median survival, 15.0 vs 19.5 days, P b .01).
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Table 1. Brief Description on the Activity and Effective Pathways of Bosutinib, Bryostatin, AZ628,
and PAC-1.
Drug Name Activity Pathway Linked to PTEN
Bosutinib Src/Abl tyrosine
kinase inhibitor
Src reverses wild-type PTEN
function and inhibits AKT.
Bryostatin PKC inhibitor Loss of PTEN activates PKC.
AZ628 Raf inhibitor Loss of PTEN cooperates with
RAS/MAPK activation.
PAC-1 Activates procaspase 3 Loss of PTEN inhibits caspase 3.
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Figure W1). These results suggest stronger loss-of- function (LOF)
effect displayed by nonsense mutations when com- pared to missense
mutations. Gata3 has been shown to antagonize cancer progression
in PTEN-deficient tumors, and this may also help to explain the
stronger adverse effect of nonsense mutations on DFS. To provide
experimental evidence for the different effects of PTEN mutations in
vivo, we established mouse xenograft models by im- planting stable
Ishikawa lines that express either nonsense (R130*) or missense
(R173H) PTEN mutations to nude mice (experimental pro- cedures
illustrated in Figure 3D). As expected, xenograft tumor tissues
bearing the nonsense PTEN mutation displayed lower levels of p53
and Gata3 proteins (Figure 3E). Because γ-H2AX is a molecular
marker for tumor genomic instability [23], we detected the level of
H2A histone family, member X (γ-H2AX) in different xenograft
tissues to validate the findings in patients with GBM. As shown in
Figure 3E, tumors bearing the nonsense PTEN mutation expressed
higher level of γ-H2AX, indicating greater genomic instability in
these tumors. In addition, the presence of nonsense PTEN mutation
also resulted in larger xenograft tumor size (Figure 3, F and G ) and
shorter survival time (Figure 3H). Taken together, these results
suggest that PTEN nonsense mutations contribute to tumorA
C
Figure 4. Nonsense PTEN mutations confer characteristic drug resp
tumor cell lines with different PTEN genotypes. On the basis of CCLE
GBM cases carrying nonsense or missense PTEN mutations using
resistance to bosutinib (A), whereas they displayed favorable respons
significant difference (P b .05).aggressiveness by increasing genomic instability and confirmed the
findings in patients with GBM.
Nonsense Mutations Display Characteristic Drug
Sensitivity Profile
To test whether PTEN nonsense mutations affect pharmacological
responses, we analyzed CCLE that includes the sensitivity profiles of
59 human brain tumor cell lines to 131 anticancer drugs [18].
The sensitivity to each drug (IC50) was compared between cell
lines carrying PTEN nonsense mutations or other mutations using
Mann-Whitney test. Interestingly, PTEN nonsense mutations
displayed lower sensitivity to the drug bosutinib [a proto-oncogeneB
D
onses. Comparison between the drug sensitivity of human brain
data set, the drug responses (IC50 values) were compared between
Mann-Whitney test. The nonsense mutations showed increased
es to bryostratin 1 (B), AZ628 (C), and PAC-1 (D). Star signs indicate
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(Src/Abl) tyrosine kinase inhibitor] than missense mutations
(Figure 4A and Table 1). Because Src inhibitors can reverse Src-A
B
C
Figure 5. Overexpression of Pten protein associates with shorter O
expression, and promoter methylation on OS of patients with GBM
tioned factors on OS, and the respective HRs are shown (with 95%
with shorter OS (P b .05, star signs). (B) Kaplan-Meier survival test rev
of Pten protein compared to other patients. (C) No association wa
Kaplan-Meier analysis. In addition, no difference was found betw
frameshift mutations.induced suppression of PTEN function [24], the ineffectiveness of
bosutinib on these cells actually suggested a stronger LOF effect of
nonsense mutations over missense mutations.S of patients with GBM. (A) Distinct effects of PTEN mutation,
. Cox regression was used to analyze the effects of abovemen-
CIs). Only the increased Pten protein level was found to associate
ealed shorter OS for patients with GBM expressing increased level
s found between OS and the mutations of PTEN, as shown by
een the OS of patients carrying PTEN missense, nonsense, or
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responses to bryostatin 1 (Sigma), AZ628 (Sigma), and procaspase
activating compound-1 (PAC-1, Sigma; Figure 4, B–D), suggesting
that the adverse effects of nonsense mutations might be targetable.
Because PTEN loss causes the activation of protein kinase C
(PKC), it is not surprising that bryostatin (PKC inhibitor) can
suppress the growth of cells carrying nonsense PTEN mutations.
Another adverse consequence of PTEN loss is the cooperation with
Ras/Raf/mitogen- activated protein kinases (MAPK) for promoting
tumorigenesis [25], and this may explain the enhanced effect of
AZ628 (a Raf inhibitor) against nonsense mutations. Finally, loss ofA
Figure 6. Increased Pten protein expression indicates substantial alte
with GBM according to the expression of different signaling protein
various pathways were obtained from RPPA data set of TCGA, and
used for the clustering. This classification well distinguished the pa
decreased Pten levels, with only one exception of 41 cases. Seve
annotation (Lawrence Berkeley National Laboratory, Berkeley, CA) su
stimulus, regulation of lipid oxidation, response to DNA damage a
apoptotic pathway. (B and C) Pten protein level is not associated with C
The CNA fraction (B) and number of mutations (C) were compared bet
protein using Mann-Whitney test, and no significant difference wasPTEN inhibits caspase 3 activity, and this may be the underlying
mechanism for the effectiveness of PAC-1 (a caspase 3 activator) on
PTEN nonsense mutations. Taken together, the drug sensitivity
profile of PTEN nonsense mutations is in good consistency with its
severe LOF phenotype and may provide important information for
its targeted therapy.
Pten Protein Up-Regulation Associates with
Shorter Overall Survival
Furthermore, we tested the effect of PTEN mutation and expres-
sion on overall survival (OS) of patients with GBM. Cox regressionB
C
ration in signaling pathways. (A) Hierarchical clustering of patients
s. The levels of signaling proteins/phosphoproteins belonging to
a hierarchical algorithm (Pearson correlation, average linkage) was
tients with increased Pten protein expression (shorter OS) or with
ral clusters of proteins were also identified, and Gene Ontology
ggested the activation of pathways involved in response to insulin
nd MAPK cascade, as well as the decreased activity of glial cell
NA fraction or number of mutations in the genomes of GBM cases.
ween GBM cases expressing increased or decreased levels of Pten
found between the two groups.
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and shorter OS (HR = 1.23, 95% CI = 1.03-1.47; Figure 5A).
Patients with upper quarter Pten protein expression displayed
significantly shorter OS (median, 7.5 months) than the rest of
patients (median, 15.7 months; Figure 5B). However, no correlation
was found between OS and PTEN mutation, mRNA level or
promoter methylation (Figure 5, A and C ).
Interestingly, patients with GBM with unregulated Pten protein
showed substantial alterations in signaling pathways involved in
insulin stimulus, lipid oxidation, DNA damage and MAPK cascade,
and inactivation of cell apoptotic process (Figure 6A). The expression
level of Pten showed no correlation with CNA fraction in genome or
the total number of mutations present in the tumor (Figure 6, B and
C). These findings suggest distinct mechanisms whereby PTEN
mutations and altered protein expression affect DFS and OS of
patients with GBM.
Discussion
Although the prognostic value of PTEN in GBM has been con-
troversial, here, we have demonstrated strong association between
PTEN mutation/expression and survival of patients with GBM.
The analysis is based on a large number of patients with
comprehensive clinical and genomic data, and the combined analysis
on genomic stability, signaling pathways, and drug sensitivity
provides mechanistic insight into the distinct effects of PTEN
mutations. We experimentally validated the effects of PTEN
mutations on genomic instability and p53/Gata3 protein levels,
thereby confirming the findings in patients with GBM.
Our analysis revealed stable association between upregulated Pten
protein and worse outcome of GBM. Patients with upper-quarter
Pten protein level showed significantly shorter median survival and
higher HR compared to the others, and this association was evident
for both OS and DFS (P b .05, Cox regression). To our knowledge,
this study presents the first analysis on the prognostic value of quanti-
fied Pten protein level for survival of patients with GBM. Meanwhile,
it should be noted that PTEN mRNA level and promoter
methylation were not associated with survival of patients with
GBM, and this may explain why previous studies focusing on mRNA
or methylation did not report any prognostic significance [26].
Interestingly, GBM with increased Pten protein level displayed
substantial alterations in signal- ing pathways involved in DNA
damage, MAPK cascade, and cell apoptotic process, which may
provide mechanistic explanations for the chemoresistant phenotype
and worse prognosis of these patients.
The distinct effects of nonsense and missense mutations of the
PTEN gene also add to the complexity of mutational effects of this
pivotal tumor suppressor. Nonsense mutations, but not missense or
frameshift mutations, were associated with shorter DFS of patients
with GBM (median survival time decreased by approximately 50%).
Consistently, only nonsense mutations were correlated to the signifi-
cant increase of mutations in the genome and the potent decrease in
p53 and Gata3 protein levels. These findings suggest stronger LOF
effects for nonsense mutations and lead to the question whether
mutations of PTEN should be equally considered when evaluating
their biologic consequences or prognostic significances. In fact,
distinct mutational effects have been well characterized for another
important tumor suppressor, p53. Hot-spot mutations of p53 confer
distinct effects on tumor spectrum and survival of mutant knock-in
mouse models [27–29], and these are considered as consequences ofdifferent LOF and GOF effects [30,31]. To determine if PTEN
mutations also display different strengths of LOF or even GOF
effects, both in vitro and in vivo studies should be carried out on the
basis of each frequently occurring mutation.
Finally, we show that the survival-shortening PTEN nonsense
mutations can be targeted by drugs that inhibit PKC (bryostatin) and
Raf (AZ628) or activate procaspase 3 (PAC_1). These findings
suggest a link between PTEN genotype and drug sensitivity profile
and encourage future studies employing PTEN status as a marker for
GBM subclassification and personalized therapeutics.
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